, China

Lee's Pharma announces H1 results

The group’s revenue is up 3.9% measured QoQ.

Chinese pharmaceutical group Lee’s Pharmaceutical Holdings Ltd. (Lee’s Pharma) has announced it took in revenue of $36,610,337 for the second quarter of this year. The revenue decreased by 12.6% compared with the same period last year, but saw an increase of 3.9% over Q1.

The total H1 revenue for the group was $71.8m which represented a reduction of 8.4% over the same period last year when the Chinese currency had weakened by 5.1% YoY. The report also showed that the sales of licensed-in products accounted for 60.9% of the group’s revenue, whilst the sales of proprietary and generic products contributed 39.1%. Net profit attributable to the owners of the company stood at $12,513,723, up 153.3% over the same period last year.

Following the slowdown in the first quarter amidst COVID-19 pandemic, the group's research and development (R&D) activities for new drugs were gradually resumed in Q2.

The group attributed the decreases in revenues to inflationary pressure on raw material costs, manufacturing and administrative overhead, and the rising tension between China and the US.

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox
It was recognised for its cutting-edge medical device packaging design, Dispenser Integrated System Kit (DISK).
There has been an expanding research base across India, China, and Japan.
It combines third-party assured data verification with blockchain technology.
Consultation is available for only $0.014 (INR1).
The number of hospitals operating on hip fracture that have access to a fracture liaison service has been steadily rising from 2013 to 2020.
GMT Manila’s award-winning initiative, in collaboration with Endec Inc. and Scilore LLC, is a rapidly deployable turnkey solution for RT-PCR Testing that made it more available across the Philippines. 
As The National Cardiovascular Referral Center in Indonesia, NCCHK has been acknowledged by Asia's Healthcare Industry.
Currently, North America dominates the market across the globe.
More medical devices are being bought for home use.
It has also introduced a new hotline service.
The firm was recognised for its multiple initiatives in braving the COVID-19 crisis.
It took home the Training Initiative of the Year trophy for its non-invasive therapy treatment for benign prostatic hyperplasia (BPH).
The country’s SII makes up about half of Covax supply.
It owns 39 hospitals and eight clinics across England, Wales, and Scotland.
The company plans to set up over 100 in-school clinics.